Table 4. The univariate and multivariate Cox regression analysis of survival in CMML patients.
| Variables | OS | PFS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| univariate analysis | multivariate analysis | univariate analysis | multivariate analysis | |||||||||
| P | HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | |
| SRSF2 mutations | 0.002 | 4.74 | 1.811–12.42 | 0.028 | 3.31 | 1.14–9.61 | 0.001 | 15.39 | 3.25–72.81 | 0.001 | 15.43 | 3.041–78.312 |
| SETBP1 mutations | 0.002 | 8.25 | 2.12–32.07 | 0.034 | 9.49 | 1.18–76.13 | 0.038 | 5.29 | 1.10–25.51 | NS | NS | NS |
| BM Blast | 0.006 | 1.18 | 1.05–1.32 | NS | NS | NS | 0.029 | 1.14 | 1.01–1.29 | NS | NS | NS |
| PB Blast | 0.02 | 1.14 | 1.02–1.27 | NS | NS | NS | 0.028 | 1.13 | 1.01–1.26 | NS | NS | NS |
| Mono | 0.015 | 1.13 | 1.02–1.25 | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| Age | 0.017 | 1.04 | 1.01–1.07 | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| HB | NS | NS | NS | NS | NS | NS | 0.038 | 0.941 | 0.941–0.998 | NS | NS | NS |
| Sex | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| WHO-subtype | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| FAB-subtype | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| WBC | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| BPC | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| Mono % | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| Cytogenetics | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
CMML, chronic myelomonocytic leukemia; OS, overall survival; PFS, progression-free survival;BM Blast, blast cell count of bone marrow; PB Blast, blast cell count of peripheral blood; WBC, white blood cell; HB, hemoglobin; BPC, blood platelet cell; Mono, monocyte; HR, hazard ratio; CI, confidence interval.